<DOC>
	<DOCNO>NCT01520831</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial demonstrate difference pharmacodynamics pharmacokinetics biphasic insulin aspart 30 , biphasic insulin aspart 50 , biphasic insulin aspart 70 insulin aspart healthy subject .</brief_summary>
	<brief_title>Comparison Biphasic Insulin Aspart ( 30 , 50 70 ) Insulin Aspart Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Body mass index 18 28 kg/m^2 inclusive HbA1c within normal laboratory range Non smoker least three month Females childbearing potential use acceptable method contraception , include tubal ligation , intrauterine device ( IUD ) , oral contraceptive pill barrier method Subjects received investigational drug 3 month prior start dose Any disease require regular use non topical prescription medicine Any serious systemic infectious disease occur 4 week prior first dose test drug Any intercurrent illness endocrine disorder may affect blood glucose Subject history drug alcohol dependence Subject first degree relative diabetes mellitus Subject history clinically relevant allergic reaction medical product Subjects donate blood plasma past 3 month precede screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>